Endothelin Receptor Antagonist

Aka: Endothelin Receptor Antagonist, Bosentan, Tracleer, Ambrisentan, Letairis, Macitentan, Opsumit, Sitaxsentan

advertisement

II. Indications

  1. Pumonary Arterial Hypertension
    1. Bosentan (Tracleer)
    2. Ambrisentan (Letairis)
    3. Macitentan (Opsumit)
    4. Sitaxsentan
  2. Hypertension (fourth-line, refractory)
    1. Aprocitentan
  3. Cancer (e.g. Prostate Cancer, Colorectal Cancer, experimental)
    1. Endothelins inhibition may decrease tumor growth, progression, and Angiogenesis

III. Mechanism

  1. Endothelin is a vasonstrictor and Aldosterone mediator
  2. Endothelin Receptor Antagonists inhibit endothelin activity, resulting in vasodilation

IV. Dosing: Pulmonary Hypertension

  1. Bosentan (Tracleer)
    1. Start 62.5 mg orally twice daily (may increase to 125 mg twice daily)
  2. Ambrisentan (Letairis)
    1. Start 5 mg daily (may increase to 10 mg daily)
  3. Macitentan (Opsumit)
    1. Start 10 mg orally daily
  4. Sitaxsentan

V. Drug Interactions

  1. Oral Contraceptives (OCP)
    1. May reduce OCP efficacy
  2. Warfarin
    1. Increased INR

VI. Adverse Effects

  1. Peripheral Edema
  2. Flushing
  3. Headache
  4. Liver Function Test abnormalities

VII. Safety

  1. FDA pregnancy category X
  2. Monitoring
    1. Liver Function Testing monthly (hepatotoxicity risk)

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Endothelin Receptor Antagonist." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Related Topics in Pharmacology

advertisement